- Companies
- NuCana
NuCana Valuation Multiples
NuCana is valued at $3M as of November 2026. In the last fiscal year, NuCana EBITDA was ($40M).
NuCana Overview
About NuCana
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
Founded
1997
HQ
Employees
22
Website
Sectors
Financials (Last FY)
Market Cap
$3M
Valuation Multiples
Start free trialNuCana Financials
NuCana reported last fiscal year revenue of - and negative EBITDA of ($40M).
In the same fiscal year, NuCana generated ($40M) in EBITDA losses and had net loss of ($39M).
NuCana P&L
In the most recent fiscal year, NuCana reported revenue of - and EBITDA of ($40M).
NuCana is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.
Financial data powered by Morningstar, Inc.
NuCana Stock Performance
NuCana has current market cap of $3M.
Market Cap Evolution
NuCana's stock price is $0.82.
NuCana has an EPS (earnings per share) of $-9.31.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $3M | -7.7% | - | - | - | $-9.31 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNuCana Valuation Multiples
NuCana Financial Valuation Multiples
As of November 19, 2026, NuCana has market cap of $3M.
NuCana has a P/E ratio of (0.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified NuCana Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


NuCana Operational KPIs
NuCana's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.2M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
NuCana Competitors
NuCana competitors include ODI Pharma, Institute of Biomedical, Apimeds Pharmaceuticals, Genxone, Spago Nanomedical, Liminatus Pharma, Scinai Immunotherapeutics, ExpreS2ion Biotech, Redhill Biopharma and Gelteq.
Most NuCana public comparables operate across Biopharmaceuticals and BioTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $3M | $248K | 0.9x | - | 12.4x | - | |||
| - | ($239K) | - | - | (14.5x) | - | |||
| - | ($6M) | - | - | (2.2x) | - | |||
| $584K | ($429K) | 4.8x | - | (6.6x) | - | |||
| $43K | ($3M) | 20.3x | - | (0.3x) | (0.3x) | |||
| - | ($10M) | - | - | (0.2x) | - | |||
| $1M | ($7M) | 8.4x | - | (1.7x) | - | |||
| $361K | ($4M) | 1.0x | - | (0.1x) | - | |||
This data is available for Pro users. Sign up to see all NuCana competitors and their valuation data. Start Free Trial | ||||||||
NuCana VC Funding History
Before going public, NuCana raised $114M in total equity funding, across 2 rounds.
NuCana Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout NuCana
| When was NuCana founded? | NuCana was founded in 1997. |
| Where is NuCana headquartered? | NuCana is headquartered in United Kingdom. |
| How many employees does NuCana have? | As of today, NuCana has over 22 employees. |
| Is NuCana publicly listed? | Yes, NuCana is a public company listed on Nasdaq. |
| What is the stock symbol of NuCana? | NuCana trades under NCNA ticker. |
| When did NuCana go public? | NuCana went public in 2017. |
| Who are competitors of NuCana? | NuCana main competitors include ODI Pharma, Institute of Biomedical, Apimeds Pharmaceuticals, Genxone, Spago Nanomedical, Liminatus Pharma, Scinai Immunotherapeutics, ExpreS2ion Biotech, Redhill Biopharma, Gelteq. |
| What is the current market cap of NuCana? | NuCana's current market cap is $3M. |
| Is NuCana profitable? | No, NuCana is not profitable. |
| What is the current net income of NuCana? | NuCana's last 12 months net income is ($39M). |
| How many companies NuCana has acquired to date? | NuCana hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies NuCana has invested to date? | NuCana hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to NuCana
Lists including NuCana
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




